Oxidative stress and apoptosis: a new treatment paradigm in cancer

被引:182
作者
Engel, RH
Evens, AM [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Div Hematol & Oncol, Chicago, IL 60611 USA
[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2006年 / 11卷
关键词
oxidative stress; reactive oxygen species; apoptosis; glutathione; cancer; review;
D O I
10.2741/1798
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Redox regulation has been shown to be an important component of malignant cell survival. Tipping the cellular redox balance through pharmacologic regulation in favor of increasing intracellular reactive oxygen species ( ROS) and/ or depleting protective reducing metabolites ( such as glutathione and nicotinamide adenine dinucleotide phosphate) may lead to oxidative stress and resultant induction of apoptosis for the treatment of cancer. We review the biology and importance of ROS with regard to malignant and normal cells. Moreover, we discuss preclinical and clinical data regarding novel therapeutic agents that modulate the cellular redox system including buthionine sulfoximine, ascorbic acid, arsenic trioxide, imexon, and motexafin gadolinium as single- agents and in combination. Continued research is needed to better understand the mechanisms and specific apoptotic pathways involved in ROS- induced cell death, as well as, to determine the most rationale and effective combination of redox- active agents.
引用
收藏
页码:300 / 312
页数:13
相关论文
共 113 条
[1]  
ARRICK BA, 1984, CANCER RES, V44, P4224
[2]  
ARRICK BA, 1982, J BIOL CHEM, V257, P1231
[3]  
Bahlis NJ, 2002, CLIN CANCER RES, V8, P3658
[4]   Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan [J].
Bailey, HH ;
Ripple, G ;
Tutsch, KD ;
Arzoomanian, RZ ;
Alberti, D ;
Feierabend, C ;
Mahvi, D ;
Schink, J ;
Pomplun, M ;
Mulcahy, RT ;
Wilding, G .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (23) :1789-1796
[5]   L-S,R-buthionine sulfoximine:: historical development and clinical issues [J].
Bailey, HH .
CHEMICO-BIOLOGICAL INTERACTIONS, 1998, 112 :239-254
[6]   ARSENIC-INDUCED TORSADE-DE-POINTES [J].
BECKMAN, KJ ;
BAUMAN, JL ;
PIMENTAL, PA ;
GARRARD, C ;
HARIMAN, RJ .
CRITICAL CARE MEDICINE, 1991, 19 (02) :290-292
[7]   Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species [J].
Bellosillo, B ;
Villamor, N ;
López-Guillermo, A ;
Marcé, S ;
Esteve, J ;
Campo, E ;
Colomer, D ;
Montserrat, E .
BLOOD, 2001, 98 (09) :2771-2777
[8]   A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma [J].
Berenson, JR ;
Swift, RA ;
Ferretti, D ;
Purner, MB .
CLINICAL LYMPHOMA, 2004, 5 (02) :130-134
[9]   DEGRADATION OF DEOXYRIBONUCLEIC ACID BY NEW TUMOUR INHIBITING COMPOUNDS - INTERMEDIATE FORMATION OF HYDROGEN PEROXIDE [J].
BERNEIS, K ;
BOLLAG, W ;
LANGEMANN, A ;
KOFLER, M ;
KAISER, A .
EXPERIENTIA, 1963, 19 (03) :132-&
[10]  
BERNEIS K, 1966, EUR J CANCER, V21, P43